Paul is a qualified European and UK Patent Attorney, and works in the Bioscience and Chemistry teams where he supports a range of clients from start-ups to multinationals. He has developed expertise with clients active in the fields of industrial biotechnology, nutrition, plant sciences, fuels and catalysts. Paul has a particular interest in Precision Medicine, and also has experience with targeted and localised therapies using a variety of therapeutic agent types. Paul also collaborates with colleagues across Keltie in order to advise on a broad range of fields, including biological modelling and medical devices.
Paul’s work includes drafting and prosecution of UK, European and International patent applications, EPO Opposition proceedings, and validity and freedom-to-operate opinions. He also manages a number of patent portfolios active in multiple countries and so has experience in examination in various jurisdictions worldwide. Likewise, he is experienced in advising attorneys and inventors on adapting strategy for inventions developed overseas to the patent system in Europe and the UK, particularly in relation to local restrictions such as for medical, diagnostic and surgical inventions.
Paul’s research experience has contributed to his interest in advising researchers and early-stage enterprises in the development of their intellectual property strategies and portfolios.
He joined Keltie in 2016, and qualified in 2021. Before this, from 2011 to 2016, Paul carried out research for a PhD in Neuroscience at the Institute of Ophthalmology at University College London, under Rachael Pearson and Robin Ali. For his doctorate he investigated cell therapy using photoreceptor precursor cells for the treatment of retinal degenerative diseases, and acquired experience in genetics and cellular neuroscience.
Paul also holds an undergraduate degree in Natural Sciences (Biological) from the University of Cambridge. During this course he studied a range of topics in the life sciences, and developed a wide area of understanding of subjects including cell biology, plant and animal physiology, pathology, and both cognitive and biological neuroscience.
08.12.2020A difference of dosage
The European Patent Office's approach to patenting new dosage regimes
31.08.2021Re-registering EU designs in the UK: Three scenarios to double check before the 30 September re-filing deadline
The deadline for re-filing EU designs in the UK is looming on 30 September 2021. Make sure your UK rights are in place before this deadline, and in particular, double check these three scenarios where your UK design rights may not have been created automatically.
15.10.2021Keltie at Nano Boston 2021
19.08.2021Unified Patent Court Update
OtherLess related knowledge